罗格列酮对胰岛素抵抗PCOS患者排卵周期影响分析

摘要

Objective To analyze the influence of rosiglitazone on ovulation of polycystic ovary syndrome(PCOS) patients with insulin resistance(IR).Methods 108 PCOS patients diagnosed with insulin resistance in our hospital during these two years were retrospectively analyzed.The patients were divided into three groups:group A orally took chlorine; group B rosiglitazone; and group C chlorine and rosiglitazone.These three groups were all treated for three menstrual cycles.The insulin resistance index (HOMA IR),free fatty acid (FFA),tumor necrosis factor alpha (TNF alpha),and the number of ovulation cycle of the 3 groups before and after the treatment were statistically analyzed and compared.Results The HOMA IR,FFA,and TNF alpha levels of group B and group C were significantly lower,with statistical differences(P ＜ 0.05).However,there was no statistical difference in group A before and after the treatment.There were no significant increases in the number of ovulation cycle in group A; while both group B and group C significantly increased in the number of ovulation cycles.The increased number of group C is obviously more than that of group B,with statistical difference(P ＜ 0.05).Conclusions Rosiglitazone can effectively improve insulin resistance and has promoting effect to the ovulation cycle of the PCOS patients with IR.%目的 分析罗格列酮对存在胰岛素抵抗(IR)的多囊卵巢综合征(PCOS)患者排卵周期的影响.方法 回顾性分析近两年来我院就诊并确诊为胰岛素抵抗的PCOS患者108例,分为三组:口服氯米芬组(A组)、口服罗格列酮组(B组)、口服氯米芬联合罗格列酮组(C组),用药三个月经周期,统计对比三组患者治疗前后胰岛素抵抗指数(HOMA-IR)、游离脂肪酸(FFA)、肿瘤坏死因子α(TNF-α)和有排卵周期例数变化的差异.结果 罗格列酮组和联合治疗组患者HOMAIR、FFA和TNF-α水平均明显降低,差异有统计学意义(P＜0.05),氯米芬组治疗前后差异无统计学意义;罗格列酮组患者有排卵周期例数增加,不显著,氯米芬组和联合治疗组有排卵周期例数明显增加,且组间比较联合治疗组增加幅度明显优于氯米芬组,差异有统计学意义(P＜0.05).结论 罗格列酮能有效改善胰岛素抵抗,对促排卵药氯米芬增加PCOS患者有排卵周期例数具有促进作用.